Bicycle Therapeutics Q2 net loss widens to $79 mln

Bicycle Therapeutics

08/08/2025 12:12

Overview

Bicycle Therapeutics reports Q2 net loss of $79 mln compared to $39.8 mln a year earlier

Company announces 30% cost realignment, primarily through workforce reduction

Cash reserves at $721.5 mln, extending financial runway into 2028

Outlook

Bicycle Therapeutics expects financial runway extended into 2028

Company anticipates 30% operational savings through strategic cost realignment

Bicycle plans FDA meeting for zelenectide pevedotin accelerated approval in Q4 2025

Initial EphA2 human imaging data expected in 2H 2025

Result Drivers

PIPELINE ADVANCEMENT - Increased R&D expenses driven by clinical program activities for zelenectide pevedotin in various cancers

COST REALIGNMENT - Strategic cost realignment, including workforce reduction, to optimize operations and extend financial runway into 2028

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$78.95 mln
Q2 Basic EPS
-$1.14
Q2 Operating Expenses
$89.52 mln
Q2 Operating Incom
-$86.60 mln
Q2 Pretax Profit
-$79.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $24.50, about 69.6% above its August 7 closing price of $7.46

Press Release: ID:nBw1Lc5H3a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)